Research presented at ECCMID outlines the identification and role of novel chromosomal mutations in the development of resistance of Escherichia coli to the broad-spectrum antibiotic fosfomycin.
The results of the MERINO trial have been reported at ECCMID, revealing the combination treatment piperacillin-tazobactam is significantly less effective than meropenem in treating some bloodstream infections.
E. coli’s internal bomb – the toxin-antitoxin system – could be triggered to make bacteria turn on themselves, offering a new target for antimicrobial approaches in drug design.
Partnership announcements and promising trial data reported at the 2018 Conference on Retroviruses and Opportunistic Infections, take a look at our round-up of the latest industry headlines.
The WHO has released its first surveillance data on antibiotic resistance, revealing that it is widespread across both low-income and high-income countries.
This research, published in Future Microbiology, screens host proteins for those that interact with EspF via flow cytometry and high-throughput screening to try and shed light on how EspF affects host cells to induce colitis and even colorectal carcinogenesis.
In a recent study published in Nature Communications, researchers demonstrated that acquired resistance to the polymixin antibiotic, colistin, can be detrimental to bacterial survival, revealing unique evolutionary trade-offs of this new form of resistance.
Mark Blaskovich gives us his thoughts on a recent study he led, published in Nature Communications, where the team re-engineered existing antibiotics to make them more powerful.
Researchers have demonstrated that antibiotic-resistance plasmids persist in the absence of antibiotics, provided that the efficiency of plasmid transfer exceeds a critical threshold, highlighting the limitations of ‘resistance-reversal’ strategies.
Researchers have analyzed the microbiomes of flies, suggesting that these insects could have more disease-carrying potential than previously thought.
